This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT03599245
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1055
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
Ocrelizumab
Sponsor
Hoffmann-La Roche